Person:
YAMAÇ, AYLİN HATİCE

Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
AYLİN HATİCE
Last Name
YAMAÇ
Name
Email Address
Birth Date

Filters

2013 - 201912020 - 20222
Reset filters

Settings

Has files: true ×

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    PublicationOpen Access
    Impact of Smoking Status on Mortality in STEMI Patients Undergoing Mechanical Reperfusion for STEMI: Insights from the ISACS-STEMI COVID-19 Registry
    (2022-11-01) De Luca G.; Algowhary M.; Uguz B.; Oliveira D. C.; Ganyukov V.; Zimbakov Z.; Cercek M.; Jensen L. O.; Loh P. H.; Calmac L.; et al.; YAMAÇ, AYLİN HATİCE
    The so-called \"smoking paradox\", conditioning lower mortality in smokers among STEMI patients, has seldom been addressed in the settings of modern primary PCI protocols. The ISACS-STEMI COVID-19 is a large-scale retrospective multicenter registry addressing in-hospital mortality, reperfusion, and 30-day mortality among primary PCI patients in the era of the COVID-19 pandemic. Among the 16,083 STEMI patients, 6819 (42.3%) patients were active smokers, 2099 (13.1%) previous smokers, and 7165 (44.6%) non-smokers. Despite the impaired preprocedural recanalization (p < 0.001), active smokers had a significantly better postprocedural TIMI flow compared with non-smokers (p < 0.001); this was confirmed after adjustment for all baseline and procedural confounders, and the propensity score. Active smokers had a significantly lower in-hospital (p < 0.001) and 30-day (p < 0.001) mortality compared with non-smokers and previous smokers; this was confirmed after adjustment for all baseline and procedural confounders, and the propensity score. In conclusion, in our population, active smoking was significantly associated with improved epicardial recanalization and lower in-hospital and 30-day mortality compared with previous and non-smoking history.
  • Thumbnail Image
    PublicationOpen Access
    Outcomes in Coronary No Reflow Phenomenon Patients and the Relationship between Kidney Injury Molecule-1 and Coronary No-Reflow Phenomenon
    (2021-02-01T00:00:00Z) Huyut, Mustafa Ahmet; YAMAÇ, AYLİN HATİCE; YAMAÇ, AYLİN HATİCE
    Background: Coronary no-reflow phenomenon (CNP) is associated with an increased risk of major cardiovascular adverse events (MACE).
  • Thumbnail Image
    PublicationOpen Access
    Utility of the Neutrophil to Lymphocyte Ratio in Predicting In-hospital Mortality in Patients That Received Levosimendan Treatment for Acute Decompensated Heart Failure
    (2013-10-01T00:00:00Z) Tasal, Abdurrahman; Surgit, Ozgur; BACAKSIZ, AHMET; Goktekin, Omer; Uyarel, Huseyin; Ergelen, Mehmet; Erdogan, Ercan; Kul, Seref; Sonmez, Osman; Turfan, Murat; Kucukbuzcu, Sitki; Vatankulu, Mehmet Akif; YAMAÇ, AYLİN HATİCE; BACAKSIZ, AHMET; YAMAÇ, AYLİN HATİCE
    Aim The aim of the study was to investigate the effect of levosimendan infusion on hematological variables in patients with acute heart failure. Also, predictive value of these variables over in hospital mortality evaluated. Methods Two hundred and nineteen patients (168 male, 51 female, mean age 63.2±12.7 years) with acute exerbation of advanced heart failure (ejection fraction ≤35%) were included in this study. Levosimendan was initiated as a bolus of 6 μg/kg followed by a continuous infusion of 0,1 μg/kg/min for 24 hours. Changes of hematological variables between admission and on third day after levosimendan infusion were evaluated. Categorical variables were expressed as frequencies and percentages. Continuous variables were compared using analysis of variance and Kruskal-Wallis tests for those with normal and skewed distributions, respectively. Chi-square tests were used to compare categorical variables. Univariate and multivariate Cox regression models were used to evaluate the independent association of different hematological variables with in-hospital mortality. Results Table 1 demonstrated the baseline demographical and laboratory characteristics of the patients. After levosimendan therapy, significant decrease in WBC and neutrophil counts and increase in lymphocyte count. As a result, neutrophil to lymphocyte ratio (NLR) decreased. Compared to patients that survived, in patients who died during in-hospital stay, these hematological changes not occurred ( Table 2 ). Δ NLR detected as independent predictor of in hospital mortality when other hematological variables associated with mortality analysed in the multivariate logistic regression analysis (R2=0.094, p=0.003). Conclusion Our study showed that levosimendan treatment is associated with significant changes in hematological variables in patients with acute exacerbation of advanced heart failure. The difference between baseline and post-treatment NLR is independent predictor of in hospital mortality.